Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.37 |
| ▸ | LOX | P28300 | 3/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 4/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | UTRN | P46939 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925194 | 0.81 | HCRTR1 (0.40) | HCRTR1HCRTR2PTGESLOXL2LOX | |
| SCHEMBL25229935 | 0.79 | PTGES (0.43) | HCRTR1HCRTR2PTGESLOXL2LOX | |
| SCHEMBL30329140 | 0.78 | RECQL (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL13164105 | 0.78 | LOXL2 (0.61) | HCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL4536253 | 0.78 | HCRTR1 (0.40) | HCRTR1HCRTR2PTGESLOXL2LOX | |
| SCHEMBL1437199 | 0.78 | RECQL (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL18083206 | 0.78 | NOS3 (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL8179984 | 0.78 | LOXL2 (0.61) | LOXL2LOXKCNH3 | |
| SCHEMBL25880968 | 0.78 | RECQL (0.42) | HCRTR1HCRTR2PTGESLOXL2LOX | |
| Hydrochloric Acid SCHEMBL25210344 | 0.77 | LOXL2 (0.59) | HCRTR1HCRTR2LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | HCRTR1 4100/4885HCRTR2 4014/4885PTGES 679/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | HCRTR1 4100/4885HCRTR2 4014/4885PTGES 679/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HCRTR1 4100/4885HCRTR2 4014/4885PTGES 679/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HCRTR1 4100/4885HCRTR2 4014/4885PTGES 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.